Liu, J. F., Barry, W. T., Birrer, M., Lee, J. -., Buckanovich, R. J., Fleming, G. F., . . . Matulonis, U. A. (2019). Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol.
استشهاد بنمط شيكاغوLiu, J F., et al. "Overall Survival and Updated Progression-free Survival Outcomes in a Randomized Phase II Study of Combination Cediranib and Olaparib Versus Olaparib in Relapsed Platinum-sensitive Ovarian Cancer." Ann Oncol 2019.
MLA استشهادLiu, J F., et al. "Overall Survival and Updated Progression-free Survival Outcomes in a Randomized Phase II Study of Combination Cediranib and Olaparib Versus Olaparib in Relapsed Platinum-sensitive Ovarian Cancer." Ann Oncol 2019.